RESEARCH PAPER
 
KEYWORDS
TOPICS
ABSTRACT
Introduction and objective:
Anti-HLA antibodies, especially anti-DSA, are believed to be potentially involved in acute and chronic rejection. New techniques, e.g. flow fluorimetry, can be an excellent supplement to the lymphocytotoxic tests currently used in pre-transplantation practice, and become a tool for monitoring post-transplant immunisation. The aim of the study was to assess the level of cytokines and alloimmunisation in kidney recipients, with the histopathological evaluation of the transplanted kidney biopsy.

Material and methods:
The study included 62 graft recipients six months after transplant. The level of anti-HLA antibodies was assessed using the x-Map Luminex technique, and the level of cytokines (IFN-γ, IL-4, IL-10, IL-17) was determined using the ELISA test.

Results:
Histopathological analysis showed that more than 45.2% of patients had changes in the biopsy material. Analysis of the level of alloimmunisation showed that in over 75.8%, the presence was detected of anti-HLA IgM class I antibodies, while anti-HLA IgM class II antibodies were found less often –17.8%. The level of anti-HLA IgG antibodies, depending on the type of the assessed class, respectively, was: class I – 43.5% and class II – 50%. More than half of the subjects also had anti-MICA antibodies. The level of analysed cytokines was low.

Conclusions:
The results indicate significant alloimmunisation of kidney recipients, although they do not answer the question whether these are antibodies that appeared de novo after transplantation, and whether anti-DSA antibodies were present among them. For this purpose, the diagnostics should be expanded to include anti-HLA monitoring in the pre- and post-transplant period, using screening tests and tests to identify their specificity. The protocol biopsy and examination of level cytokine can also be a helpful tool in post-transplant diagnosis.

Wojciechowska-Koszko I, Nowosiad-Magda M, Krasnodębska-Szponder B, Roszkowska P, Sławiński M, Kwiatkowski P. Evaluation of the level of alloantibodies and selected cytokines in kidney recipients. J Pre-Clin Clin Res. 2022; 16(4): 131–136. doi: 10.26444/jpccr/157283
REFERENCES (24)
1.
Nowaczyk M. Podstawy immunologii transplantacyjnej. Immunologiczny dobór dawców i biorców narządów unaczynionych. http://klinikamedycynytranspla... (Access on 15 Nov 2022).
 
2.
Sorohan NB, Baston C, Tacu D, et al. Non-HLA antibodies in kidney transplantation: Immunity and genetic insights. Biomedicines. 2022;10 (7):506. https://doi.org/10.3390/biomed....
 
3.
Wiebe Ch, Kosmoliaptsis V, Pochinco D, et al. A comparison of HLA molecular mismatch methods to determine HLA immunogenicity. Transplantation. 2018;102(8):1338–1343. https://doi.org/10.1097/TP.000....
 
4.
Chong AS, Rothstein DM, Safa K, et al. Outstanding questions in transplantation: B cell, alloantibodies, and humoral rejection. Am J Transplant. 2019;19(8):2155–2163. https://doi.org/10.1111/ajt.15....
 
5.
Przybyciński J, Kwiatkowska E, Marchelek-Myśliwiec M, et al. Pacjenci wysokoimmunizowani jako problem dzisiejszej transplantologii — opis przypadku i przegląd literatury. Forum Nefrologiczne. 2018;11(3):176– 186.
 
6.
Lai WL, Yeh TH, Chen PH, et al. Membranous nephropathy: A review on the pathogenesis, diagnosis, and treatment. J Formos Med Assoc. 2015;114(2):102–11. https://doi.org/10.1016/j.jfma....
 
7.
Cioni M, Nocera A, Tagliamacco A, et al. Failure to remove de novo donor specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody mediated rejection destined to graft loss – a retrospective study. Transpl Int. 2019;32(1):38–48. https://doi.org/10.1111/tri.13....
 
8.
Mehrotra S, Sharma RK, Maya M, et al. Luminex solid-phase crossmatch for de novo donor-specific antibodies in living-donor related rransplants. Exp Clin Transplant. 2015;15(4):394–399. https:// doi.org/10.6002/ect.2016.0178.
 
9.
Zielińska H, Moszkowska G, Dębska-Ślizień A, et al. Możliwości diagnostyczne oceny ryzyka immunologicznego biorcy nerki przed przeszczepieniem i po jego wykonaniu. Forum Nefrologiczne 2011;4(4):320–330.
 
10.
Zielińska H. Rozprawa na stopień doktora nauk medycznych. Algorytm oceny poziomu alloprzeciwciał anty-HLA specyficznych.
 
11.
dla dawcy w surowicy biorców przeszczepu nerki. Gdański Uniwersytet Medyczny. Katedra Immunologii, Zakład Immunologii Klinicznej i Transplantologii; 2014.
 
12.
Perkowska-Ptasińska A. Diagnostyka zmian w nerce przeszczepowej. Pol J Pathol. 2011;1(1):111–149.
 
13.
Sawosz M, Bączkowska T. Biopsje protokolarne nerki przeszczepionej. Forum Nefrologiczne. 2012;5(2):105–109.
 
14.
Barlow AD. Kidney transplantation. Surgery. 2020;38(7):398–404. https://doi.org/10.1016/j.mpsu....
 
15.
Cynthia S, Kramer M, Moshe I, et al. The long and winding road towards epitope matching in clinical transplantation. Transpl Int. 2019;32(1):16–24. https://doi.org/10.1111/tri.13....
 
16.
Lopes D, Barra T, Malheiro J, et al. Effect of different sensitisation events on HLA alloimmunization in kidney transplantation candidates. Transplant Proceedings. 2015;47(4):894–897.
 
17.
Mahovald GK. The CDC crossmatch in the era of flow cytometric crossmatch and single antigen beads. Braz J Nephrol. 2021;43(3):299–300.
 
18.
Dedlinská N, Mačková K, Machálaková K, et al. Flow Cytometry panelreactive antibody screening of anti-HLA antibodies in the waiting list significantly reduces the occurrence of acute rejection after kidney transplantation. Transplantation Proceedings. 2017;49(8):1719–1723. https://doi.org/10.1016/j.tran....
 
19.
Togninalli M, Yoneoka D, Kolios AGA, et al. Pretransplant kinetics of anti-HLA antibodies in patients on the waiting list for kidney transplantation. J Am Soc Nephrol. 2019;30(11):2262–2274. https:// doi.org/10.1681/ASN.2019060594.
 
20.
Fu SM, Lim SM, Jalalonmuhali M, et al. Clinical significance of renal allograft protocol biopsies: A single tertiary center experience in Malaysia. J Transplant. 2019; 9153875. https://doi.org/10.1155/2019/9....
 
21.
Cosio FG, Ters EM, Cornell LD, et al. Changing kidney allograft histology early posttransplant: Prognostic implications of 1-year protocol biopsies. Am J Transplant. 2016;16:194–203. https://doi.org/10.1111/ajt.13....
 
22.
Pernin V, Cros A, Szwarc I, et al. HLA alloimmunization according to the different immunisation events and consequences on access to kidney transplantation. 2017 American Transplant Congress. https:// atcmeetingabstracts.com/abstract/hla-alloimmunization-accordingto- the-different-immunization-events-and-consequences-on-accessto- kidney-transplantation/ (Access on 15 Nov 2022).
 
23.
Pandey P, Pande A, Mandal S, et al. Effects of different sensitisation events on HLA alloimmunisation in renal transplant cases; a retrospective observation in 1066 cases. Transpl Immunol. 2022;75:101680. https:// doi.org/10.1016/j.trim.2022.101680.
 
24.
Sadeghi M, Daniel V, Naujokat C, et al. Evidence for IFN-gamma upand IL-4 downregulation late post-transplant in patients with good kidney graft outcome. Clin Transplant. 2007; 21(4): 449–59. https://doi. org/10.1111/j.1399-0012.2007.00665.x.
 
eISSN:1898-7516
ISSN:1898-2395
Journals System - logo
Scroll to top